Pediatric Dermatology
Upadacitinib Appears Effective Against Atopic Dermatitis in Teens and Adults
Two phase 3, placebo-controlled studies suggest the oral Janus kinase (JAK) inhibitor upadacitinib is effective for moderate-to-severe atopic dermatitis (AD),